drugset
drugset / Trial / NCT06672393

A Study to Confirm Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis

NCT06672393 ↗

Phase 3 Not yet recruiting 375 enrolled Hansoh BioMedical R&D Company
RandomizedParallel-groupDouble-blindTreatment

Summary

This study has been designed to confirm the clinical efficacy and safety of HS-10374 in the treatment of moderate to severe plaque psoriasis.

Timeline

Start
2024-11-04
Primary completion
2025-10-22
Completion
2026-06-29

Drugs

EvaluationDrugModalityDoseRoute
Subject HS-10374 Unknown 6 mg Oral

Indications

psoriasis